Market Overview

VeriFone Systems: Imperial Stays On Sidelines

VeriFone Systems: Imperial Stays On Sidelines

Imperial Capital remains sidelined on VeriFone Systems Inc (NYSE: PAY) with an In-Line rating and $18 price target after the company issued modest outlook for 2017 given slower EMV adoption.

VeriFone noted that FY 2017 revenue could decline by roughly 4 percent year-over-year (yoy). The company sees revenue of $1.89 billion–$1.91 billion due to the payment networks’ decision to delay the liability shift deadline for EMV at-the-pump by three years, above industry expectations of one year.

This assumes significance, as nearly 5 million terminals in the United States still require upgrades and U.S. EMV upgrades will be an important growth driver for VeriFone.

Brokerage's Commentary

But, the brokerage is not surprised by this decision of payment networks, as its checks showed most owners of gas station and convenient stores were not interested in upgrading their terminals over the next twelve months due to the high costs.

“However, we view the company's partnership with Gilbarco (gasoline fuel dispenser and retail petroleum technology provider) as a positive and think that this could enable VeriFone to improve its market penetration as it enters FY18,” analyst Saliq Khan wrote in a note.

But, the delay in EMV certifications in the United States is hurting the implementation process of higher margin attached services.

Shares of VeriFone closed Friday trading at $18.43.

Latest Ratings for PAY

Apr 2018DowngradesBuyHold
Apr 2018DowngradesBuyHold
Apr 2018MaintainsNeutralNeutral

View More Analyst Ratings for PAY
View the Latest Analyst Ratings

Posted-In: Analyst Color News Guidance Price Target Reiteration Analyst Ratings Movers Tech Best of Benzinga


Related Articles (PAY)

View Comments and Join the Discussion!
Need corporate guidance data?
Click here to see licensing options.

Latest Ratings

ARAVH.C. WainwrightReiterates31.0
KMPHH.C. WainwrightReiterates2.5
HASusquehannaInitiates Coverage On27.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Live Cattle Futures Little Changed

Jefferies' Huge Pharma Pair Trade: Bristol-Myers Upgraded To Buy, Merck Downgraded To Sell